Mora Guardamagna, Medical Oncologist at Institut Gustave Roussy, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Delighted to share our latest article on immunotherapy sequencing in melanoma, published in Journal for ImmunoTherapy of Cancer (JITC)!
Evidence on the optimal treatment sequence is still limited. In this study, we present a cohort of 190 patients, incorporating the recently approved rela/nivo into the treatment sequence, to evaluate its efficacy and safety in the current therapeutic landscape.”
Title: International real-world study of combination immunotherapy sequences in metastatic melanoma
Authors: Mora Guardamagna, Sarah E Lochrin, James William Smithy, Michael Postow, Caroline Gaudy-Marqueste, Nausicaa Malissen, Sandrine Monestier, Ryan J Sullivan, Juliane A Czapla, Aleigha R Lawless, Ines Pires da Silva, Georgina V Long, Alexander Maxwell Menzies, Florentia Dimitriou, Reinhard Dummer, Caroline Marchi, Amandine Chaurand, Stéphane Dalle, Paolo A Ascierto, Miriam Paone, Bianca Arianna Facchini, Govind Warrier, Evan J Lipson, Michael Erdmann, Carola Berking, Baptiste Archambaud, Severine Roy, Emilie Routier, Celine Boutros, Philippe Jamme, Djaouida Belkadi-Sadou, Noemie Simon-Tillaux, Caroline Robert
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Mora Guardamagna.